Current and future perspectives in unresectable locally advanced esophageal squamous cell cancer (Review)
- Authors:
- Weijia Zhang
- Min Zhu
- Ying Xiang
- Yujiao Sun
- Shuang Li
- Jun Cai
- Hai Zeng
-
Affiliations: Department of Oncology, First Affiliated Hospital of Yangtze University, Jingzhou, Hubei 434000, P.R. China, Department of Clinical Medicine, Medical School of Yangtze University, Jingzhou, Hubei 434000, P.R. China - Published online on: March 8, 2024 https://doi.org/10.3892/or.2024.8724
- Article Number: 65
This article is mentioned in:
Abstract
|
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Maomao C, He L, Dianqin S, Siyi H, Xinxin Y, Fan Y, Shaoli Z, Changfa X, Lin L, Ji P and Wanqing C: Current cancer burden in China: Epidemiology, etiology, and prevention. Cancer Biol Med. 19:1121–1138. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Njei B, McCarty TR and Birk JW: Trends in esophageal cancer survival in United States adults from 1973 to 2009: A SEER database analysis. J Gastroenterol Hepatol. 31:1141–1146. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Sasaki Y and Kato K: Chemoradiotherapy for esophageal squamous cell cancer. Jpn J Clin Oncol. 46:805–810. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Huang FL and Yu SJ: Esophageal cancer: Risk factors, genetic association, and treatment. Asian J Surg. 41:210–215. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, et al: Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 366:2074–2084. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Teoh AY, Chiu PW, Yeung WK, Liu SY, Wong SK and Ng EK: Long-term survival outcomes after definitive chemoradiation versus surgery in patients with resectable squamous carcinoma of the esophagus: Results from a randomized controlled trial. Ann Oncol. 24:165–171. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Chen P, Zhao X, Zhou F, Song X, Hu S, Jin Y, Wang X, Han X, Fan Z, Wang R, et al: Characterization of 500 Chinese patients with cervical esophageal cancer by clinicopathological and treatment outcomes. Cancer Biol Med. 17:219–226. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA Jr, Al-Sarraf M, Byhardt R, Russell AH, Beitler JJ, Spencer S, et al: Chemoradiotherapy of locally advanced esophageal cancer: Long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation therapy oncology group. JAMA. 281:1623–1627. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Zeng H, Zhang F, Sun Y, Li S and Zhang W: Treatment options for neoadjuvant strategies of esophageal squamous cell carcinoma (review). Mol Clin Oncol. 20:42023. View Article : Google Scholar : PubMed/NCBI | |
|
Ferri L: Clinical T4b esophageal cancer: Can we make an ‘unresectable’ tumour resectable? Ann Surg Oncol. 27:329–330. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Yamaguchi S, Morita M, Yamamoto M, Egashira A, Kawano H, Kinjo N, Tsujita E, Minami K, Ikebe M, Ikeda Y, et al: Long-term outcome of definitive chemoradiotherapy and induction chemoradiotherapy followed by surgery for T4 esophageal cancer with tracheobronchial invasion. Ann Surg Oncol. 25:3280–3287. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Yokota T, Kato K, Hamamoto Y, Tsubosa Y, Ogawa H, Ito Y, Hara H, Ura T, Kojima T, Chin K, et al: A 3-year overall survival update from a phase 2 study of chemoselection with DCF and subsequent conversion surgery for locally advanced unresectable esophageal cancer. Ann Surg Oncol. 27:460–467. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Mitchell KG, Nelson DB, Corsini EM, Vaporciyan AA, Antonoff MB, Mehran RJ, Rice DC, Roth JA, Sepesi B, Walsh GL, et al: Morbidity following salvage esophagectomy for squamous cell carcinoma: The MD Anderson experience. Dis Esophagus. 33:doz0672020.PubMed/NCBI | |
|
Miyata H, Sugimura K, Kanemura T, Takeoka T, Sugase T, Tanaka K, Makino T, Yamashita K, Yamasaki M, Motoori M, et al: Salvage surgery for recurrent disease after definitive chemoradiotherapy for esophageal squamous cell carcinoma. Ann Surg Oncol. 29:5657–5665. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, Okawara G, Rosenthal SA and Kelsen DP: INT 0123 (radiation therapy oncology group 94-05) phase III trial of combined-modality therapy for esophageal cancer: High-dose versus standard-dose versus standard-dose radiation therapy. J Clin Oncol. 20:1167–1174. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Ji Y, Du X, Zhu W, Yang Y, Ma J, Zhang L, Li J, Tao H, Xia J, Yang H, et al: Efficacy of concurrent chemoradiotherapy with S-1 vs radiotherapy alone for older patients with esophageal cancer: A multicenter randomized phase 3 clinical trial. JAMA Oncol. 7:1459–1466. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Conroy T, Galais MP, Raoul JL, Bouché O, Gourgou-Bourgade S, Douillard JY, Etienne PL, Boige V, Martel-Lafay I, Michel P, et al: Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): Final results of a randomised, phase 2/3 trial. Lancet Oncol. 15:305–314. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG and Morrow M: Esophagus. American Joint Committee on Cancer (AJCC) cancer staging manual. 6th edition. New York, NY: Springer; pp. 167–178. 2002 | |
|
Rades D, Zwaan I, Soror T, Idel C, Pries R, Bruchhage KL, Hakim SG and Yu NY: Chemoradiation with cisplatin vs carboplatin for squamous cell carcinoma of the head and neck (SCCHN). Cancers (Basel). 15:32782023. View Article : Google Scholar : PubMed/NCBI | |
|
Ai D, Ye J, Wei S, Li Y, Luo H, Cao J, Zhu Z, Zhao W, Lin Q, Yang H, et al: Comparison of 3 paclitaxel-based chemoradiotherapy regimens for patients with locally advanced esophageal squamous cell cancer: A randomized clinical trial. JAMA Netw Open. 5:e2201202022. View Article : Google Scholar : PubMed/NCBI | |
|
Higuchi K, Komori S, Tanabe S, Katada C, Azuma M, Ishiyama H, Sasaki T, Ishido K, Katada N, Hayakawa K, et al: Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: A phase 2 trial (KDOG 0501-P2). Int J Radiat Oncol Biol Phys. 89:872–879. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou XL, Yu CH, Wang WW, Ji FZ, Xiong YZ, Zhu WG and Tong YS: Concurrent chemoradiotherapy with S-1 compared with concurrent chemoradiotherapy with docetaxel and cisplatin for locally advanced esophageal squamous cell carcinoma. Radiat Oncol. 16:942021. View Article : Google Scholar : PubMed/NCBI | |
|
Wang X, Han W, Zhang W, Wang X, Ge X, Lin Y, Zhou H, Hu M, Wang W, Liu K, et al: Effectiveness of S-1-based chemoradiotherapy in patients 70 years and older with esophageal squamous cell carcinoma: A randomized clinical trial. JAMA Netw Open. 6:e23126252023. View Article : Google Scholar : PubMed/NCBI | |
|
Li J, Gong Y, Diao P, Huang Q, Wen Y, Lin B, Cai H, Tian H, He B, Ji L, et al: Comparison of the clinical efficacy between single-agent and dual-agent concurrent chemoradiotherapy in the treatment of unresectable esophageal squamous cell carcinoma: A multicenter retrospective analysis. Radiat Oncol. 13:122018. View Article : Google Scholar : PubMed/NCBI | |
|
Herskovic A, Martz K, al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, Cooper J, Byhardt R, Davis L and Emami B: Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 326:1593–1598. 1992. View Article : Google Scholar : PubMed/NCBI | |
|
Itami J, Murakami N, Watanabe M, Sekii S, Kasamatsu T, Kato S, Hirowatari H, Ikushima H, Ando K, Ohno T, et al: Combined interstitial and intracavitary high-dose rate brachytherapy of cervical cancer. Front Oncol. 11:8098252022. View Article : Google Scholar : PubMed/NCBI | |
|
Lan W, Lihong L, Chun H, Shutang L, Qi W, Liang X, Xiaoning L and Likun L: Comparison of efficacy and safety between simultaneous integrated boost intensity-modulated radiotherapy and standard-dose intensity-modulated radiotherapy in locally advanced esophageal squamous cell carcinoma: A retrospective study. Strahlenther Onkol. 198:802–811. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Chen Y, Zhu HP, Wang T, Sun CJ, Ge XL, Min LF, Zhang XW, Jia QQ, Yu J, Yang JQ, et al: What is the optimal radiation dose for non-operable esophageal cancer? Dissecting the evidence in a meta-analysis. Oncotarget. 8:89095–89107. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Xu Y, Dong B, Zhu W, Li J, Huang R, Sun Z, Yang X, Liu L, He H, Liao Z, et al: A phase III multicenter randomized clinical trial of 60 Gy versus 50 Gy radiation dose in concurrent chemoradiotherapy for inoperable esophageal squamous cell carcinoma. Clin Cancer Res. 28:1792–1799. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Hulshof MCCM, Geijsen ED, Rozema T, Oppedijk V, Buijsen J, Neelis KJ, Nuyttens JJME, van der Sangen MJC, Jeene PM, Reinders JG, et al: Randomized study on dose escalation in definitive chemoradiation for patients with locally advanced esophageal cancer (ARTDECO study). J Clin Oncol. 39:2816–2824. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Crehange G, M'vondo C, Bertaut A, Pereira R, Rio E, Peiffert D, Gnep K, Benezery K, Ronchin P, Noel G, et al: Exclusive chemoradiotherapy with or without radiation dose escalation in esophageal cancer: Multicenter phase 2/3 randomized trial CONCORDE (PRODIGE-26). Int J Radiat Oncol Biol Phys. 111 (Suppl):S52021. View Article : Google Scholar | |
|
Chandra A, Guerrero TM, Liu HH, Tucker SL, Liao Z, Wang X, Murshed H, Bonnen MD, Garg AK, Stevens CW, et al: Feasibility of using intensity-modulated radiotherapy to improve lung sparing in treatment planning for distal esophageal cancer. Radiother Oncol. 77:247–253. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Nicolini G, Ghosh-Laskar S, Shrivastava SK, Banerjee S, Chaudhary S, Agarwal JP, Munshi A, Clivio A, Fogliata A, Mancosu P, et al: Volumetric modulation arc radiotherapy with flattening filter-free beams compared with static gantry IMRT and 3D conformal radiotherapy for advanced esophageal cancer: A feasibility study. Int J Radiation Oncol Biol Phys. 84:553–560. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Wang X, Bai H, Li R, Wang L, Zhang W, Liang J and Yuan Z: High versus standard radiation dose of definitive concurrent chemoradiotherapy for esophageal cancer: A systematic review and meta-analysis of randomized clinical trials. Radiother Oncol. 180:1094632023. View Article : Google Scholar : PubMed/NCBI | |
|
Welsh J, Palmer MB, Ajani JA, Liao Z, Swisher SG, Hofstetter WL, Allen PK, Settle SH, Gomez D, Likhacheva A, et al: Esophageal cancer dose escalation using a simultaneous integrated boost technique. Int J Radiat Oncol Biol Phys. 82:468–474. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Wang R, Liu S, Chen B and Xi M: Recent advances in combination of immunotherapy and chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. Cancers (Basel). 14:51682022. View Article : Google Scholar : PubMed/NCBI | |
|
Gao XS, Qiao X, Wu F, Cao L, Meng X, Dong Z, Wang X, Gao G, Wu TT, Komaki R and Chang JY: Pathological analysis of clinical target volume margin for radiotherapy in patients with esophageal and gastroesophageal junction carcinoma. Int J Radiat Oncol Biol Phys. 67:389–396. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Yang H and Hu B: Recent advances in early esophageal cancer: Diagnosis and treatment based on endoscopy. Postgrad Med. 133:665–673. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Vesprini D, Ung Y, Dinniwell R, Breen S, Cheung F, Grabarz D, Kamra J, Mah K, Mansouri A, Pond G, et al: Improving observer variability in target delineation for gastro-oesophageal cancer-the role of (18F)fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography. Clin Oncol (R Coll Radiol). 20:631–638. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Pijl JP, Nienhuis PH, Kwee TC, Glaudemans AWJM, Slart RHJA and Gormsen LC: Limitations and pitfalls of FDG-PET/CT in infection and inflammation. Semin Nucl Med. 51:633–645. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Fernandez P, Zanotti-Fregonara P, Eimer S, Gimbert E, Monteil P, Penchet G, Lamare F, Perez P, Vimont D, Ledure S, et al: Combining 3′-Deoxy-3′-[18F] fluorothymidine and MRI increases the sensitivity of glioma volume detection. Nucl Med Commun. 40:1066–1071. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Han D, Yu J, Yu Y, Zhang G, Zhong X, Lu J, Yin Y, Fu Z, Mu D, Zhang B, et al: Comparison of (18)F-fluorothymidine and (18)F-fluorodeoxyglucose PET/CT in delineating gross tumor volume by optimal threshold in patients with squamous cell carcinoma of thoracic esophagus. Int J Radiat Oncol Biol Phys. 76:1235–1241. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Guo Y, Li J, Zhang P and Zhang Y: A comparative study of target volumes based on 18F-FDG PET-CT and ten phases of 4DCT for primary thoracic squamous esophageal cancer. Onco Targets Ther. 10:177–184. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Vollenbrock SE, Voncken FEM, van Dieren JM, Lambregts DMJ, Maas M, Meijer GJ, Goense L, Mook S, Hartemink KJ, Snaebjornsson P, et al: Diagnostic performance of MRI for assessment of response to neoadjuvant chemoradiotherapy in oesophageal cancer. Br J Surg. 106:596–605. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Li H, Li F, Li J, Zhu Y, Zhang Y, Guo Y, Xu M, Shao Q and Liu X: Comparison of gross target volumes based on four-dimensional CT, positron emission tomography-computed tomography, and magnetic resonance imaging in thoracic esophageal cancer. Cancer Med. 9:5353–5361. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Van De Voorde L, Larue RT, Pijls M, Buijsen J, Troost EG, Berbée M, Sosef M, van Elmpt W, Schraepen MC, Vanneste B, et al: A qualitative synthesis of the evidence behind elective lymph node irradiation in oesophageal cancer. Radiother Oncol. 113:166–174. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Tamamura H, Hasatani K, Matsumoto S, Asahi S, Tatebe H, Sato Y, Matsusita K, Tameshige Y, Maeda Y, Sasaki M, et al: Evaluation of exposure doses of elective nodal irradiation in chemoradiotherapy for advanced esophageal cancer. Cancers (Basel). 15:8602023. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao KL, Ma JB, Liu G, Wu KL, Shi XH and Jiang GL: Three-dimensional conformal radiation therapy for esophageal squamous cell carcinoma: Is elective nodal irradiation necessary? Int J Radiat Oncol Biol Phys. 76:446–451. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Wang J, Wu Y, Zhang W, Chen Y, Liu Q, Jing S, Zhang J, Wu F, Wang J and Qiao X: Elective nodal irradiation versus involved-field irradiation for stage II–IV cervical esophageal squamous cell carcinoma patients undergoing definitive concurrent chemoradiotherapy: a retrospective propensity study with 8-year survival outcomes. Radiat Oncol. 18:1422023. View Article : Google Scholar : PubMed/NCBI | |
|
Chen X, Zhang Y, Zhou X, Wang M, Na F, Zhou L, Xu Y, Zou B, Xue J, Liu Y and Gong Y: Involved-field irradiation or elective-nodal irradiation in neoadjuvant chemo-radiotherapy for locally-advanced esophageal cancer: Comprehensive analysis for dosimetry, treatment-related complications, impact on lymphocyte, patterns of failure and survival. Front Oncol. 13:12749242023. View Article : Google Scholar : PubMed/NCBI | |
|
Lyu J, LI T, Zhang X, Tian Z, Wang X, Chen L, LU B, Chen H, Yang J, Wang Q, et al: Involved field irradiation (IFI) versus elective nodal irradiation (ENI) in combination with concurrent chemotherapy for esophageal thoracic squamous cell cancer: A prospective, randomized, multicenter, controlled study. Chin J Radiat Oncol. 7:245–249. 2018. | |
|
Rahim MK, Okholm TLH, Jones KB, McCarthy EE, Liu CC, Yee JL, Tamaki SJ, Marquez DM, Tenvooren I, Wai K, et al: Dynamic CD8+ T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes. Cell. 186:1127–1143. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Wang X, Bai H, Gao M, Guan Y, Yu L, Li J, Dong Y, Song Y, Tao Z, Meng M, et al: Impact of radiation dose to the immune system on disease progression and survival for early-stage non-small cell lung cancer treated with stereotactic body radiation therapy. Radiother Oncol. 186:1098042023. View Article : Google Scholar : PubMed/NCBI | |
|
Reid TD, Davies IL, Mason J, Roberts SA, Crosby TD and Lewis WG: Stage for stage comparison of recurrence patterns after definitive chemoradiotherapy or surgery for oesophageal carcinoma. Clin Oncol (R Coll Radiol). 24:617–624. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Z, Guo J, Qin J, Zhang H, Zhao Y, Lu Y, Yan X, Zhang F, Zhang Z, Zhang T, et al: Accuracy of 3-T MRI for preoperative T staging of esophageal cancer after neoadjuvant chemotherapy, with histopathologic correlation. Am J Roentgenol. 212:788–795. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Kim SW, Kim IK and Lee SH: Role of hyperoxic treatment in cancer. Exp Biol Med (Maywood). 245:851–860. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Cavalieri S and Licitra L: Induction chemotherapy is the best timekeeper in nasopharyngeal carcinoma. Cancer. 126:3624–3626. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Qiu J, Lin H, Yu Y, Ke D, Li H, Zheng H, Zheng Q, Wang Z, Lin M, Yang J, et al: Clinical outcomes and toxicities of locally advanced esophageal squamous cell carcinoma patients treated with early thoracic radiation therapy after induction chemotherapy. Int J Clin Oncol. 28:550–564. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Wang XS, Xi M, Bu SS, Xu G and Ge H: Comparative analysis between induction chemotherapy combined with concurrent chemoradiotherapy and chemoradiotherapy alone for thoracic esophageal squamous cell carcinoma. Chin J Radiat Oncol. 28:90–95. 2019. | |
|
Minsky BD, Neuberg D, Kelsen DP, Pisansky TM, Ginsberg R and Benson A III: Neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus: A preliminary analysis of the phase II intergroup trial 0122. J Clin Oncol. 14:149–155. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Liu S, Luo L, Zhao L, Zhu Y, Liu H, Li Q, Cai L, Hu Y, Qiu B, Zhang L, et al: Induction chemotherapy followed by definitive chemoradiotherapy versus chemoradiotherapy alone in esophageal squamous cell carcinoma: A randomized phase II trial. Nat Commun. 12:40142021. View Article : Google Scholar : PubMed/NCBI | |
|
Chan WL, Choi CW, Wong IY, Tsang TH, Lam AT, Tse RP, Chan KK, Wong C, Law BT, Cheung EE, et al: Docetaxel, cisplatin, and 5-FU triplet therapy as conversion therapy for locoregionally advanced unresectable esophageal squamous cell carcinoma. Ann Surg Oncol. 30:861–870. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Xi M, Liao Z, Deng W, Komaki R, Ho L and Lin SH: Recursive partitioning analysis identifies pretreatment risk groups for the utility of induction chemotherapy before definitive chemoradiation therapy in esophageal cancer. Int J Radiat Oncol Biol Phys. 99:407–416. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Wang J, Xiao L, Wang S, Pang Q and Wang J: Addition of induction or consolidation chemotherapy in definitive concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone for patients with unresectable esophageal cancer: A systematic review and meta-analysis. Front Oncol. 11:6652312021. View Article : Google Scholar : PubMed/NCBI | |
|
Waters JK and Reznik SI: Update on management of squamous cell esophageal cancer. Curr Oncol Rep. 24:375–385. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Xia X, Wu M, Gao Q, Sun X and Ge X: Consolidation chemotherapy rather than induction chemotherapy can prolong the survival rate of inoperable esophageal cancer patients who received concurrent chemoradiotherapy. Curr Oncol. 29:6342–6349. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang AD, Su XH, Shi GF, Han C, Wang L, Liu H, Zhang J and Zhang RH: Survival comparision of three-dimensional radiotherapy alone vs chemoradiotherapy for esophageal squamous cell carcinoma. Arch Med Res. 51:419–428. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Xia X, Liu Z, Qin Q, Di X, Zhang Z, Sun X and Ge X: Long-term survival in nonsurgical esophageal cancer patients who received consolidation chemotherapy compared with patients who received concurrent chemoradiotherapy alone: A systematic review and meta-analysis. Front Oncol. 10:6046572021. View Article : Google Scholar : PubMed/NCBI | |
|
Chen Y, Guo L, Cheng X, Wang J, Zhang Y, Wang Y, Ke S and Shi W: With or without consolidation chemotherapy using cisplatin/5-FU after concurrent chemoradiotherapy in stage II–III squamous cell carcinoma of the esophagus: A propensity score-matched analysis. Radiother Oncol. 129:154–160. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao Z, Zhang Y, Wang X, Geng X, Zhu L and Li M: Clinical response to chemoradiotherapy in esophageal carcinoma is associated with survival and benefit of consolidation chemotherapy. Cancer Med. 9:5881–5888. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Wu Z, Zheng Q, Chen H, Xiang J, Hu H, Li H, Pan Y, Peng Y, Yao X, Liu P, et al: Efficacy and safety of neoadjuvant chemotherapy and immunotherapy in locally resectable advanced esophageal squamous cell carcinoma. J Thorac Dis. 13:3518–3528. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Sun JM, Shen L, Shah MA, Enzinger P, Adenis A, Doi T, Kojima T, Metges JP, Li Z, Kim SB, et al: Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): A randomised, placebo-controlled, phase 3 study. Lancet. 398:759–771. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Peng F, Bao Y, Cheng C, Niu S, Song W, Li Y, Yu H, Xing X, Feng S, Wang X, et al: Induction chemotherapy plus camrelizumab followed by concurrent chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma (ImpactCRT): A single-arm, phase II trial. J Clin Oncol. 41 (Suppl 16):e160672023. View Article : Google Scholar | |
|
Jing Z, Du D, Zhang N, Dai H, Wang X, Hua Y and Wu S: Combination of radiation therapy and anti-PD-1 antibody SHR-1210 in treating patients with esophageal squamous cell cancer. Int J Radiat Oncol Biol Phys. 102:E312018. View Article : Google Scholar | |
|
Zhang W, Yan C, Gao X, Li X, Cao F, Zhao G, Zhao J, Er P, Zhang T, Chen X, et al: Safety and feasibility of radiotherapy plus camrelizumab for locally advanced esophageal squamous cell carcinoma. Oncologist. 26:e1110–e1124. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang W, Yan C, Zhang T, Chen X, Dong J, Zhao J, Han D, Wang J, Zhao G, Cao F, et al: Addition of camrelizumab to docetaxel, cisplatin, and radiation therapy in patients with locally advanced esophageal squamous cell carcinoma: A phase 1b study. OncoImmunology. 10:19714182021. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu Y, Wen J, Li Q, Chen B, Zhao L, Liu S, Yang Y, Wang S, Lv Y, Li J, et al: Toripalimab combined with definitive chemoradiotherapy in locally advanced oesophageal squamous cell carcinoma (EC-CRT-001): A single-arm, phase 2 trial. Lancet Oncol. 24:371–382. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Calabrò L, Morra A, Giannarelli D, Amato G, D'Incecco A, Covre A, Lewis A, Rebelatto MC, Danielli R, Altomonte M, et al: Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): An open-label, non-randomised, phase 2 study. Lancet Respir Med. 6:451–460. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Kelley RK, Sangro B, Harris W, Ikeda M, Okusaka T, Kang YK, Qin S, Tai DWM, Lim HY, Yau T, et al: Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: Randomized expansion of a phase I/II study. J Clin Oncol. 39:2991–3001. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Park S, Oh D, Choi YL, Chi SA, Kim K, Ahn MJ and Sun JM: Durvalumab and tremelimumab with definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. Cancer. 128:2148–2158. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL and Trotti A: AJCC cancer staging manual. 7th edition. New York, NY: Springer; 2010 | |
|
Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, Mendez G, Feliciano J, Motoyama S, Lièvre A, et al: Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med. 384:1191–1203. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Wang J, Cheng Y, Wu Y, Cao F, Liu Q and Gao G: 978P A prospective study of camrelizumab monotherapy following definitive concurrent chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell cancer. Ann Oncol. 32 (Suppl 5):S8382021. View Article : Google Scholar | |
|
Bando H, Kumagai S, Kotani D, Saori M, Habu T, Tsushima T, Hara H, Kadowaki S, Kato K, Chin K, et al: 1211P A multicenter phase II study of atezolizumab monotherapy following definitive chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma (EPOC1802). Ann Oncol. 33 (Suppl 7):S1102–S1103. 2022. View Article : Google Scholar | |
|
Yang YM, Hong P, Xu WW, He QY and Li B: Advances in targeted therapy for esophageal cancer. Signal Transduct Target Ther. 5:2292020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao G, Feng L, Ye T, Liu Y, Fan L, Ye C and Chen J: Cetuximab enhances radiosensitivity of esophageal squamous cell carcinoma cells by G2/M cycle arrest and DNA repair delay through inhibiting p-EGFR and p-ERK. Thorac Cancer. 14:2127–2138. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Brenner B, Purim O, Gordon N, Goshen-Lago T, Idelevich E, Kashtan H, Menasherov N, Fenig E, Sulkes A and Kundel Y: The addition of cetuximab to preoperative chemoradiotherapy for locally advanced esophageal squamous cell carcinoma is associated with high rate of long term survival: Mature results from a prospective phase Ib/II trial. Radiother Oncol. 134:74–80. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Crosby T, Hurt CN, Falk S, Gollins S, Mukherjee S, Staffurth J, Ray R, Bashir N, Bridgewater JA, Geh JI, et al: Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): A multicentre, phase 2/3 randomised trial. Lancet Oncol. 14:627–637. 2013. View Article : Google Scholar : PubMed/NCBI |
